

## Akynzeo<sup>®</sup> (fosnetupitant/palonosetron) – New formulation

- On April 20, 2018, <u>Helsinn announced</u> the FDA approval of <u>Akynzeo (fosnetupitant/palonosetron)</u> injection, in combination with <u>dexamethasone</u> in adults for the prevention of acute and delayed nausea and vomiting (N/V) associated with initial and repeat courses of highly emetogenic cancer chemotherapy.
  - Akynzeo for injection has not been studied for the prevention of N/V associated with anthracycline plus cyclophosphamide chemotherapy.
- Akynzeo is also available as oral capsules indicated in combination with dexamethasone in adults for the prevention of acute and delayed N/V associated with initial and repeat courses of cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy.
- Akynzeo for injection contains palonosetron and fosnetupitant, a prodrug of netupitant. Palonosetron prevents N/V during the acute phase and fosnetupitant prevents N/V during both the acute and delayed phase after cancer chemotherapy.
- The bioequivalence of Akynzeo for injection with the oral formulation of netupitant was demonstrated, and the safety of Akynzeo for injection was established through a repeated dose safety study in cancer patients. No anaphylactic and injection site reactions related to Akynzeo for injection were reported in the study.
- Similar to Akynzeo capsules, the warnings and precautions of Akynzeo for injection include hypersensitivity and serotonin syndrome.
- The safety profile of Akynzeo for injection was generally similar to that seen with Akynzeo capsules. The most common adverse reactions (≥ 3%) with Akynzeo capsule use were headache, asthenia, dyspepsia, fatigue, constipation, and erythema.
- The recommended dose of Akynzeo for injection is one vial infused intravenously 30 minutes before chemotherapy on day 1.
  - Dexamethasone 12 mg should be administered 30 minutes before chemotherapy on day 1. Then, dexamethasone 8 mg should be administered once daily on days 2 to 4.
- Helsinn plans to launch Akynzeo for injection in May 2018. Akynzeo for injection will be available as a lyophilized powder in a single-dose vial containing 235 mg fosnetupitant and 0.25 mg palonosetron for reconstitution.



OptumRx<sup>®</sup> specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum<sup>®</sup> company — a leading provider of integrated health services. Learn more at **optum.com**.

All Optum<sup>®</sup> trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2018 Optum, Inc. All rights reserved.